BCAX
Bicara Therapeutics
BCAX
BCAX
147 hedge funds and large institutions have $1.4B invested in Bicara Therapeutics in 2026 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 58 increasing their positions, 40 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
4% more funds holding
Funds holding: 141 → 147 (+6)
62% less call options, than puts
Call options by funds: $1.52M | Put options by funds: $4M
Holders
147
Holding in Top 10
8
Calls
$1.52M
Puts
$4M
Top Buyers
| 1 | +$58M | |
| 2 | +$31.8M | |
| 3 | +$24.9M | |
| 4 |
RPSM
Royalty Pharma Sub-Manager
New York
|
+$19.4M |
| 5 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
+$18.2M |
Top Sellers
| 1 | -$21.5M | |
| 2 | -$4.79M | |
| 3 | -$3.96M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.16M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$1.68M |
